+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
ID07671417

Early-Phase Imaging Study of RYZ512 to Evaluate Safety, Biodistribution, and Radiation Dose in Metastatic Clear Cell Renal Cell Carcinoma

Led by RayzeBio, Inc. · Updated on 2026-10-13

10

Participants Needed

6

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an imaging agent called RYZ512 in people with metastatic clear cell renal cell carcinoma RCC. This early-phase study aims to determine if this imaging agent is feasible to use, how it spreads throughout the body, and how much radiation dose is absorbed by organs and tumors. The study focuses on assessing the tolerability and biodistribution of RYZ512 in affected individuals. Participants will receive the imaging agent RYZ512 during the study. The research team will monitor how the agent distributes in the body over time and measure radiation doses absorbed by critical organs and tumors. This is a diagnostic study designed to collect detailed imaging data and dosimetry information over a six-month period. During the study, participants will undergo imaging assessments and evaluations to track the agents behavior in the body. Researchers will monitor safety and tolerability while collecting data on radiation exposure and biodistribution. The total study duration for each participant is approximately six months, during which multiple imaging and safety assessments will take place to gather comprehensive information.

CONDITIONS

Brief Title

Imaging Study in Metastatic Clear Cell RCC.

Research Team

R

RayzeBio Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here